Neumora Therapeutics (NMRA) Competitors $0.63 -0.03 (-3.96%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock NMRA vs. GHRS, ALMS, QURE, BCYC, KURA, URGN, MGTX, IMTX, ARVN, and SIONShould you be buying Neumora Therapeutics stock or one of its competitors? The main competitors of Neumora Therapeutics include GH Research (GHRS), Alumis (ALMS), uniQure (QURE), Bicycle Therapeutics (BCYC), Kura Oncology (KURA), UroGen Pharma (URGN), MeiraGTx (MGTX), Immatics (IMTX), Arvinas (ARVN), and Sionna Therapeutics (SION). These companies are all part of the "pharmaceutical products" industry. Neumora Therapeutics vs. GH Research Alumis uniQure Bicycle Therapeutics Kura Oncology UroGen Pharma MeiraGTx Immatics Arvinas Sionna Therapeutics Neumora Therapeutics (NASDAQ:NMRA) and GH Research (NASDAQ:GHRS) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, valuation, community ranking, risk, earnings, media sentiment, institutional ownership and dividends. Do analysts prefer NMRA or GHRS? Neumora Therapeutics currently has a consensus target price of $9.29, suggesting a potential upside of 1,373.92%. GH Research has a consensus target price of $30.86, suggesting a potential upside of 254.68%. Given Neumora Therapeutics' higher possible upside, research analysts clearly believe Neumora Therapeutics is more favorable than GH Research.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Neumora Therapeutics 1 Sell rating(s) 5 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.22GH Research 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community prefer NMRA or GHRS? GH Research received 1 more outperform votes than Neumora Therapeutics when rated by MarketBeat users. Likewise, 76.92% of users gave GH Research an outperform vote while only 76.32% of users gave Neumora Therapeutics an outperform vote. CompanyUnderperformOutperformNeumora TherapeuticsOutperform Votes2976.32% Underperform Votes923.68% GH ResearchOutperform Votes3076.92% Underperform Votes923.08% Which has more risk & volatility, NMRA or GHRS? Neumora Therapeutics has a beta of 2.89, meaning that its share price is 189% more volatile than the S&P 500. Comparatively, GH Research has a beta of 0.84, meaning that its share price is 16% less volatile than the S&P 500. Is NMRA or GHRS more profitable? GH Research's return on equity of -20.29% beat Neumora Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Neumora TherapeuticsN/A -73.63% -68.97% GH Research N/A -20.29%-19.49% Which has higher valuation and earnings, NMRA or GHRS? GH Research is trading at a lower price-to-earnings ratio than Neumora Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNeumora TherapeuticsN/AN/A-$235.93M-$1.53-0.41GH ResearchN/AN/A-$35.59M-$0.75-11.60 Does the media favor NMRA or GHRS? In the previous week, Neumora Therapeutics had 6 more articles in the media than GH Research. MarketBeat recorded 6 mentions for Neumora Therapeutics and 0 mentions for GH Research. GH Research's average media sentiment score of 1.89 beat Neumora Therapeutics' score of 0.58 indicating that GH Research is being referred to more favorably in the news media. Company Overall Sentiment Neumora Therapeutics Positive GH Research Very Positive Do institutionals and insiders believe in NMRA or GHRS? 47.7% of Neumora Therapeutics shares are owned by institutional investors. Comparatively, 56.9% of GH Research shares are owned by institutional investors. 26.4% of Neumora Therapeutics shares are owned by company insiders. Comparatively, 41.6% of GH Research shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. SummaryGH Research beats Neumora Therapeutics on 11 of the 15 factors compared between the two stocks. Remove Ads Get Neumora Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NMRA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NMRA vs. The Competition Export to ExcelMetricNeumora TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$102.05M$2.85B$5.28B$7.36BDividend YieldN/A1.91%5.11%4.32%P/E Ratio-0.3430.3821.6317.68Price / SalesN/A433.44371.0892.88Price / CashN/A168.6838.1534.64Price / Book0.213.416.373.94Net Income-$235.93M-$72.06M$3.20B$247.45M7 Day Performance-16.63%0.83%1.79%0.48%1 Month Performance-50.78%-18.82%-9.41%-7.08%1 Year Performance-94.25%-30.46%9.61%-0.35% Neumora Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NMRANeumora Therapeutics3.1659 of 5 stars$0.63-4.0%$9.29+1,373.9%-94.1%$102.05MN/A-0.34108GHRSGH Research3.0822 of 5 stars$9.32-7.6%$30.86+231.1%-23.3%$484.90MN/A-11.8010Gap DownHigh Trading VolumeALMSAlumis2.4092 of 5 stars$10.07+0.2%$26.00+158.2%N/A$475.53MN/A0.00N/AGap DownHigh Trading VolumeQUREuniQure2.1719 of 5 stars$8.76-2.2%$38.80+342.9%+103.6%$473.72M$27.12M-1.77500Short Interest ↑Gap DownBCYCBicycle Therapeutics1.9283 of 5 stars$6.75-2.0%$29.14+331.7%-64.3%$467.11M$35.28M-2.05240Gap DownKURAKura Oncology4.1563 of 5 stars$5.76-2.2%$25.50+342.7%-68.3%$465.15M$53.88M-2.44130URGNUroGen Pharma3.9198 of 5 stars$9.96-2.8%$38.20+283.5%-28.8%$459.10M$90.40M-3.16200Analyst ForecastNews CoveragePositive NewsMGTXMeiraGTx4.5747 of 5 stars$5.75+1.2%$24.50+326.1%-0.4%$453.42M$33.28M-4.75300Gap DownHigh Trading VolumeIMTXImmatics2.4826 of 5 stars$3.68+5.1%$16.67+352.9%-58.0%$439.23M$155.84M-5.58260Short Interest ↓News CoveragePositive NewsHigh Trading VolumeARVNArvinas3.571 of 5 stars$6.37-2.9%$35.50+457.3%-78.2%$438.08M$263.40M-2.30420Short Interest ↓Positive NewsGap DownHigh Trading VolumeSIONSionna TherapeuticsN/A$9.73-2.4%$38.50+295.7%N/A$429.33MN/A0.0035 Remove Ads Related Companies and Tools Related Companies GH Research Competitors Alumis Competitors uniQure Competitors Bicycle Therapeutics Competitors Kura Oncology Competitors UroGen Pharma Competitors MeiraGTx Competitors Immatics Competitors Arvinas Competitors Sionna Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NMRA) was last updated on 4/16/2025 by MarketBeat.com Staff From Our PartnersTrump Makes Major Crypto AnnouncementTrump Ends the “War on Crypto” I expect it to pump the market, which is why I'm recommending ONE coin to al...Crypto 101 Media | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredDOGE tax surpriseElon Musk's DOGE agents have some very strange plans for the IRS... Recently, it emerged that our tax auth...Altimetry | SponsoredIs it CRAZY to still want reliable profits, despite this market?Larry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredFirst look: The $3,500 iPhoneDid you hear that just before Trump's tariffs took effect, Apple sent five cargo planes packed with MacBooks a...Stansberry Research | SponsoredMarkets in Chaos? Here’s What to Do.Wall Street's on edge with tariffs. And volatility? It's not slowing down. You've seen the headlines… Bu...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neumora Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Neumora Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy NMRA Stock Free NMRA Stock Alerts